SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, George Magrath, MD, MBA, MS, CEO of Ocuphire Pharma, provides an update on APX3330 for the treatment of diabetic retinopathy.
APX3330 is “well tolerated, and really shows promise to potentially slow or prevent the progression of non-proliferative diabetic retinopathy to vision-threatening disease,” he said.
Magrath also discussed the results of the end-of-phase 2 meeting with the FDA for APX3330.